布地奈德联合特布他林雾化吸入治疗儿童支原体肺炎的疗效

目的 探讨布地奈德联合特布他林雾化吸入治疗儿童支原体肺炎的疗效。方法 选取镇安县医院2018年1月~12月诊断为肺炎支原体的患儿100例，采用随机数字表法分为对照组和观察组，各50例。对照组给予阿奇霉素治疗，观察组在对照组基础上给予布地纳德联合特布他林雾化吸入治疗，比较两组治疗总有效率、临床症状（发热、咳嗽、肺部湿罗音）消失时间、住院时间以及临床不良反应。结果 观察组治疗总有效率（94.00%）高于对照组（80.00%），差异有统计学意义（P＜0.05）；观察组发热消失时间（4.25±1.21）d、咳嗽消失时间（4.54±1.24）d、肺部湿罗音消失时间（4.25±1.12）d、住院时间（8.20±1.36）d短于对照组的（5.89±1.26）d、（7.48±1.72）d、（6.00±1.45）d、（11.14±2.45）d，差异有统计学意义（P＜0.05）；观察组不良反应发生率（6.00%）与对照组（8.00%）比较，差异无统计学意义（P＞0.05）。结论 布地奈德联合特布他林雾化吸入治疗可作为儿童支原体肺炎的辅助药物，可促进临床症状消退，且临床不良反应少，治疗安全有效。

Efficacy of Budesonide Combined with Terbutaline Atomization Inhalation in the Treatment of Children with Mycoplasmal Pneumonia

Objective To investigate the efficacy of budesonide combined with terbutaline atomization inhalation in the treatment of children with mycoplasmal pneumonia. Methods A total of 100 children diagnosed as Mycoplasma pneumoniae from January to December 2018 in Zhenan County Hospital of Shaanxi Province were randomly divided into the control group and the observation group, 50 cases each. The control group was treated with azithromycin. The observation group was given budesonide combined with terbutaline atomization inhalation on the basis of the control group. The total effective rate and clinical symptoms (fever, cough, lung wet rales) disappeared, hospital stay and clinical adverse reactions. Results The total effective rate of treatment in the observation group (94.00%) was higher than that in the control group (80.00%), the difference was statistically significant (P<0.05); the disappearance time of fever in the observation group (4.25±1.21) d, the disappearance time of cough (4.54±1.24) d, the time of disappearance of wet rales in the lungs (4.25±1.12) d, the length of hospital stay (11.14±2.45) d was shorter than that of the control group (5.89±1.26)d, (7.48±1.72)d, (6.00±1.45)d, (8.20±1.36)d, the difference was statistically significant (P<0.05);The incidence of adverse reactions in the observation group (6.00%) was not significantly different from that in the control group (8.00%) (P>0.05). Conclusion Budesonide combined with terbutaline atomization inhalation therapy can be used as an adjuvant drug for children with mycoplasmal pneumonia, which can promote the clinical symptoms, and has fewer clinical adverse reactions. The treatment is safe and effective.